Sudarshan Pharma Industries Limited (BOM:543828)
India · Delayed Price · Currency is INR 25.70
-0.02 (-0.08%)
At close: Feb 12, 2026
BOM:543828 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 6,437 | 5,050 | 4,635 | 4,613 | 3,571 | 1,934 |
Other Revenue | - | - | - | - | - | 1.74 |
| 6,437 | 5,050 | 4,635 | 4,613 | 3,571 | 1,935 | |
Revenue Growth (YoY) | 40.15% | 8.95% | 0.48% | 29.19% | 84.52% | 30.77% |
Cost of Revenue | 5,681 | 4,398 | 4,226 | 4,310 | 3,354 | 1,795 |
Gross Profit | 756.43 | 652.05 | 409.86 | 303.72 | 217.06 | 139.86 |
Selling, General & Admin | 88.3 | 70.27 | 47.49 | 41.93 | 30.82 | 19.84 |
Other Operating Expenses | 181.47 | 175.32 | 125.44 | 109.59 | 76.08 | 45.95 |
Operating Expenses | 299.2 | 267.8 | 185.38 | 160.59 | 115.56 | 73.22 |
Operating Income | 457.23 | 384.25 | 224.48 | 143.12 | 101.5 | 66.64 |
Interest Expense | -206.33 | -141.04 | -78.7 | -45.86 | -27.58 | -28.56 |
Interest & Investment Income | 5.55 | 5.55 | 7.88 | 4.9 | 1.99 | 0.25 |
Currency Exchange Gain (Loss) | 2.01 | 2.01 | 1.95 | 0.13 | 0.11 | 1.1 |
Other Non Operating Income (Expenses) | 21.42 | -6.3 | -3.33 | -4.95 | -3.67 | -3.69 |
EBT Excluding Unusual Items | 279.87 | 244.47 | 152.28 | 97.34 | 72.35 | 35.75 |
Gain (Loss) on Sale of Assets | - | - | - | -2.37 | -0.99 | - |
Other Unusual Items | -16.48 | -28.17 | - | - | - | - |
Pretax Income | 263.39 | 216.29 | 152.28 | 94.96 | 71.36 | 35.75 |
Income Tax Expense | 59.59 | 56.77 | 37.73 | 24.6 | 18.87 | 9.03 |
Earnings From Continuing Operations | 203.8 | 159.53 | 114.55 | 70.37 | 52.49 | 26.71 |
Minority Interest in Earnings | 5.99 | 0.02 | - | - | -0.01 | - |
Net Income | 209.78 | 159.55 | 114.55 | 70.37 | 52.48 | 26.71 |
Net Income to Common | 209.78 | 159.55 | 114.55 | 70.37 | 52.48 | 26.71 |
Net Income Growth | 93.25% | 39.28% | 62.79% | 34.09% | 96.46% | 109.49% |
Shares Outstanding (Basic) | 248 | 242 | 239 | 241 | 144 | 153 |
Shares Outstanding (Diluted) | 251 | 242 | 239 | 241 | 144 | 153 |
Shares Change (YoY) | 3.91% | 1.30% | -0.83% | 66.88% | -5.63% | - |
EPS (Basic) | 0.85 | 0.66 | 0.48 | 0.29 | 0.36 | 0.17 |
EPS (Diluted) | 0.83 | 0.66 | 0.48 | 0.29 | 0.36 | 0.17 |
EPS Growth | 85.98% | 37.50% | 64.16% | -19.65% | 108.19% | 109.49% |
Free Cash Flow | - | 302.13 | 59.02 | -431.2 | -54.79 | 14.7 |
Free Cash Flow Per Share | - | 1.25 | 0.25 | -1.79 | -0.38 | 0.10 |
Dividend Per Share | - | - | - | 0.030 | - | - |
Gross Margin | 11.75% | 12.91% | 8.84% | 6.58% | 6.08% | 7.23% |
Operating Margin | 7.10% | 7.61% | 4.84% | 3.10% | 2.84% | 3.44% |
Profit Margin | 3.26% | 3.16% | 2.47% | 1.52% | 1.47% | 1.38% |
Free Cash Flow Margin | - | 5.98% | 1.27% | -9.35% | -1.53% | 0.76% |
EBITDA | 466.03 | 394.55 | 236.77 | 152.19 | 110.15 | 72.88 |
EBITDA Margin | 7.24% | 7.81% | 5.11% | 3.30% | 3.08% | 3.77% |
D&A For EBITDA | 8.8 | 10.3 | 12.29 | 9.07 | 8.66 | 6.24 |
EBIT | 457.23 | 384.25 | 224.48 | 143.12 | 101.5 | 66.64 |
EBIT Margin | 7.10% | 7.61% | 4.84% | 3.10% | 2.84% | 3.44% |
Effective Tax Rate | 22.63% | 26.24% | 24.78% | 25.90% | 26.45% | 25.27% |
Revenue as Reported | 483,271 | - | 4,661 | 4,624 | 3,576 | 1,937 |
Advertising Expenses | - | 0.21 | 0.28 | 0.07 | 0.04 | 0.09 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.